Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 238

Sort by

Sort Order Select

Journal Articles

A new role for hematoxylin: targeting CALR

Julia E. Maxson

Blood (2021) 137 (14): 1848–1849.

https://doi.org/10.1182/blood.2020009852

Published: 2021

Journal Articles

Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor

Ruochen Jia, Thomas Balligand, Vasyl Atamanyuk, Harini Nivarthi, Erica Xu, Leon Kutzner, Jakob Weinzierl, Audrey Nedelec, Stefan Kubicek, Roman Lesyk, Oleh Zagrijtschuk, Stefan N. Constantinescu, Robert Kralovics

Blood (2021) 137 (14): 1920–1931.

https://doi.org/10.1182/blood.2020006264

Published: 2021

Includes: Supplemental data

Journal Articles

Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms in mice

Kotaro Shide, Takuro Kameda, Ayako Kamiunten, Yoshinori Ozono, Yuki Tahira, Takako Yokomizo-Nakano, Sho Kubota, Masaya Ono, Kazuhiko Ikeda, Masaaki Sekine, Keiichi Akizuki, Kenichi Nakamura, Tomonori Hidaka, Yoko Kubuki, Hisayoshi Iwakiri, Satoru Hasuike, Kenji Nagata, Goro Sashida, Kazuya Shimoda

Blood (2020) 136 (1): 106–118.

https://doi.org/10.1182/blood.2019003358

Published: 2020

Includes: Supplemental data

Journal Articles

Mutant CALR functions: gains and losses

Daniel Prins, Anthony R. Green

Blood (2020) 136 (1): 6–7.

https://doi.org/10.1182/blood.2020005805

Published: 2020

Journal Articles

MDS/MPN-U with persistent monocytosis, del(20q), and CALR mutation, the great masquerader

Zhaodong Xu, Brian R. Berry

Blood (2020) 135 (19): 1718.

https://doi.org/10.1182/blood.2020004897

Published: 2020

Journal Articles

Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms

Christian A. Di Buduo, Vittorio Abbonante, Caroline Marty, Francesco Moccia, Elisa Rumi, Daniela Pietra, Paolo M. Soprano, Dmitry Lim, Daniele Cattaneo, Alessandra Iurlo, Umberto Gianelli, Giovanni Barosi, Vittorio Rosti, Isabelle Plo, Mario Cazzola, Alessandra Balduini

Blood (2020) 135 (2): 133–144.

https://doi.org/10.1182/blood.2019001103

Published: 2020

Includes: Supplemental data

Journal Articles

Both sides now: losses and gains of mutant CALR

Ann Mullally

Blood (2020) 135 (2): 82–83.

https://doi.org/10.1182/blood.2019003820

Published: 2020

Journal Articles

Mutant calreticulin in myeloproliferative neoplasms

Joan How, Gabriela S. Hobbs, Ann Mullally

Blood (2019) 134 (25): 2242–2248.

https://doi.org/10.1182/blood.2019000622

Published: 2019

Journal Articles

Mutant CALR in MPN

Blood (2019) 134 (25): 2331.

https://doi.org/10.1182/blood.2019003984

Published: 2019

Journal Articles

Calr Mutational Status in Egyptian Patients with Myeloproliferative Neoplams

Eman A. Soliman, MD, Samah I. El-Ghlban, MD PhD, Abdelaleem H. Abdelaleem, MD PhD, Sherin Abdel-Aziz, MD PhD, Sameh Shamaa, MD PhD, Hasan A. Abdel-ghaffar, MD PhD

Blood (2019) 134 (Supplement_1): 5388.

https://doi.org/10.1182/blood-2019-128194

Published: 2019

Journal Articles

The Frequency of Calr and MPL Gene Mutations in Jak2 V617F - Positive Chronic Myeloproliferative Neoplasms in Russia

Tatiana V Makarik, PhD, Adhamjon O Abdullaev, MD PhD, Sergei M. Kulikov, PhD, Elena E Nikulina, Svetlana A Treglazova, Irina N Subortseva, MD, Alla M. Kovrigina, MD PhD, Anait L. Melikyan, MD PhD, Andrey B Sudarikov, PhD DSc, Valery G. Savchenko, MD PhD academician

Blood (2019) 134 (Supplement_1): 5400.

https://doi.org/10.1182/blood-2019-124767

Published: 2019

Journal Articles

Dual Driver Mutant BCR-ABL1-Negative Myeloid Neoplasms: Multicenter Clinicopathologic and Genomic Analysis

Zachary D. Epstein-Peterson, MD, Joseph Tripodi, Maria E Arcila, MD, Filiz Sen, MD, Vesna Najfeld, PhD, John Mascarenhas, MD, Ronald Hoffman, MD, Rajit K. Rampal, MD, PhD

Blood (2019) 134 (Supplement_1): 4173.

https://doi.org/10.1182/blood-2019-125379

Published: 2019

Journal Articles

Integrated Genomic-Transcriptomic Study Highlights Accumulation of Genetic Variants and Activation of Inflammatory Pathways

Malathi Kandarpa, PhD, Kristen Pettit, MD, Tingting Qin, PhD, Yi-Mi Wu, PhD, Dan Robinson, PhD, Maureen Sartor, PhD, Arul Chinnaiyan, MD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 4212.

https://doi.org/10.1182/blood-2019-128301

Published: 2019

Journal Articles

Predicting the Long-Term Efficacy of Ifnα in JAK2 V617F and Calr -Mutated MPN Patients

Blood (2019) 134 (Supplement_1): 4196.

https://doi.org/10.1182/blood-2019-127903

Published: 2019

Journal Articles

Knock-Ins of Type-2 Calr Mutants Cause Myeloproliferative Neoplasm (MPN)-like Hematopoiesis in Mice

Keiji Minakawa, Koki Ueda, MD PhD, Osamu Nakajima, Tetsuro Yokokawa, MD, Yusuke Kinishima, MD, Tomofumi Misaka, MD PhD, Kazuei Ogawa, MD PhD, Takayuki Ikezoe, MD PhD, Yasuchika Takeishi, MD PhD, Kazuhiko Ikeda, MD PhD

Blood (2019) 134 (Supplement_1): 2964.

https://doi.org/10.1182/blood-2019-124575

Published: 2019

Journal Articles

Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs)

Paola Guglielmelli, MD PhD, Niccolò Bartalucci, PhDBSc, Elisa Contini, PhD, Giada Rotunno, PhD, Annalisa Pacilli, PhD, Simone Romagnoli, BSc, Lara Mannelli, MD, Francesco Mannelli, MD, Giacomo Coltro, MD, Alessandro Pancrazzi, PhD, Valentina Ariu, BSci, Sara Fiaccabrino, Roberto Semeraro, Alberto Magi, PhD, Carmela Mannarelli, PhD, Francesca Gesullo, BSci, Chiara Paoli, PhD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 2968.

https://doi.org/10.1182/blood-2019-129094

Published: 2019

Journal Articles

Acquired Resistance to JAK Inhibitors in Calr-Mutated Myeloproliferative Neoplasms

Ken-Hong Lim, MD, Yu-Cheng Chang, MD, Yi-Hao Chiang, MD, Huan-Chau Lin, MD, Ling Huang, MSc, Wei-Ting Wang, MSc, Ying-Wen Su, MD, PhD, Ming-Chih Chang, MD, Yi-Fang Chang, MD PhD, Caleb Gon-Shen Chen, MD PhD

Blood (2019) 134 (Supplement_1): 2970.

https://doi.org/10.1182/blood-2019-124420

Published: 2019

Journal Articles

Dysregulated IL-6/GP130/JAK Signaling in Calreticulin Mutated Myeloproliferative Neoplasms (MPN)

Manjola Balliu, PhD, Laura Calabresi, PhD, Niccolò Bartalucci, PhDBSc, Laura Maggi, PhD, Francesco Annunziato, PhD, Paola Guglielmelli, MD PhD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 471.

https://doi.org/10.1182/blood-2019-123685

Published: 2019

Journal Articles

Stroke and Myocardial Infarction (MI) in Hereditary Thrombotic Thrombocytopenic Purpura (HTTP): Similarities to Sickle Cell Anemia (SSA)

Azra Borogovac, MD, James George, MD

Blood (2019) 134 (Supplement_1): 1079.

https://doi.org/10.1182/blood-2019-122208

Published: 2019

Journal Articles

Elevated Plasma sIL-2Rα Levels in Primary Myelofibrosis Play a Distinct Role on Disease Progression in JAK2V617F and Calr Mutants

Giovanni Barosi, Rita Campanelli, Paolo Catarsi, Mara De Amici, Carlotta Abbà, MSc, Gianluca Viarengo, Laura Villani, Margherita Massa, Vittorio Rosti, MD

Blood (2019) 134 (Supplement_1): 1678.

https://doi.org/10.1182/blood-2019-125531

Published: 2019

NARROW

A new role for hematoxylin: targeting CALR

Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor

Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms in mice

Mutant CALR functions: gains and losses

MDS/MPN-U with persistent monocytosis, del(20q), and CALR mutation, the great masquerader

Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms

Both sides now: losses and gains of mutant CALR

Mutant calreticulin in myeloproliferative neoplasms

Mutant CALR in MPN

Calr Mutational Status in Egyptian Patients with Myeloproliferative Neoplams

The Frequency of Calr and MPL Gene Mutations in Jak2 V617F - Positive Chronic Myeloproliferative Neoplasms in Russia

Dual Driver Mutant BCR-ABL1-Negative Myeloid Neoplasms: Multicenter Clinicopathologic and Genomic Analysis

Integrated Genomic-Transcriptomic Study Highlights Accumulation of Genetic Variants and Activation of Inflammatory Pathways

Predicting the Long-Term Efficacy of Ifnα in JAK2 V617F and Calr -Mutated MPN Patients

Knock-Ins of Type-2 Calr Mutants Cause Myeloproliferative Neoplasm (MPN)-like Hematopoiesis in Mice

Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs)

Acquired Resistance to JAK Inhibitors in Calr-Mutated Myeloproliferative Neoplasms

Dysregulated IL-6/GP130/JAK Signaling in Calreticulin Mutated Myeloproliferative Neoplasms (MPN)

Stroke and Myocardial Infarction (MI) in Hereditary Thrombotic Thrombocytopenic Purpura (HTTP): Similarities to Sickle Cell Anemia (SSA)

Elevated Plasma sIL-2Rα Levels in Primary Myelofibrosis Play a Distinct Role on Disease Progression in JAK2V617F and Calr Mutants

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only